Press Releases
At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 12, 2015
Pulmatrix, Inc. (NASDAQ: PULM) reports third quarter financial results and provides an update on the progress year to date on the business and its drug development pipeline. Since the beginning of...
- Oct 9, 2015
Pulmatrix, Inc., (NASDAQ: PULM) will be webcasting the Company's investor presentation at two upcoming investor conferences. Pulmatrix will be presenting at the Dawson James 2015 Small Cap Growth...
-
Oct 8, 2015Data to be Presented at 2015 North American Cystic Fibrosis Conference
Pulmatrix, Inc. (NASDAQ: PULM) today announced preclinical data showing that PUR1900 (iSPERSE™-formulated itraconazole), which is being developed as the first inhaled antifungal medication for...
-
Oct 1, 2015
Celdara Medical, LLC and Pulmatrix, Inc. (NASDAQ: PULM) today announced that the National Heart Lung and Blood Institute of the National Institutes of Health has awarded a three-year, $1.7 million...
- Sep 23, 2015- Results to be Presented September 29th at 2015 European Respiratory Society Congress -
Pulmatrix, Inc. (NASDAQ: PULM) will report data from a Phase 1B study evaluating PUR0200, an iSPERSE formulation of a long acting muscarinic antagonist (LAMA) bronchodilator, on September 29th at...
